Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem DOI Creative Commons
Saeed Hassani,

Meshkat Mesh Poortavakol,

Mohammad Sayyadi

и другие.

Iranian Journal of Blood and Cancer, Год журнала: 2022, Номер 14(4), С. 125 - 139

Опубликована: Дек. 1, 2022

thrombotic thrombocytopenia (VITT) Covid-19 vaccination Platelet factor 4(PF-4)The common reported adverse impacts of COVID-19 include the injection site's local reaction followed by various non-specific flu-like symptoms.Nevertheless, uncommon cases vaccine-induced immune and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported.This literature review was performed using PubMed Google Scholar databases appropriate keywords their combinations: SARS-CoV-2, adenovirus, spike protein, thrombosis, thrombocytopenia, (VITT), NF-kappaB, adenoviral vector, platelet 4 (PF4), Vaccine, AstraZeneca COVID ChAdOx1 AZD1222 coagulopathy.The abstracts titles each article were assessed authors for screening inclusion English reports about post-vaccine CVST VITT in humans also collected.Some SARS-CoV-2 based on mRNA, or inactivated virus accepted are being pragmatic global.Nevertheless, recent augmented statistics normally very infrequent types associated with stated, predominantly context vaccine from Astra Zeneca.The numerical prevalence these side effects seems to associate this particular type, i.e., vector-based vaccines, but meticulous molecular mechanisms still not clear.The present summarizes latest data hypotheses cellular into one integrated hypothesis demonstrating that coagulopathies, including thromboses, other effects, correlated an interaction two components vaccine.

Язык: Английский

Covid-19 vaccination and menstrual bleeding disturbances among women of fertile age: a Norwegian registry study DOI Creative Commons
Maria C. Magnus, Ida Henriette Caspersen, Knut‐Arne Wensaas

и другие.

European Journal of Epidemiology, Год журнала: 2024, Номер 39(10), С. 1127 - 1138

Опубликована: Окт. 1, 2024

Abstract This study evaluated the relationship between Covid-19 vaccination and menstrual bleeding disturbances using a large national registry linkage including 666,467 women 20 40 years of age residing in Norway on January 1st, 2019. Information vaccination—BNT162b2 mRNA-1273 — was obtained from Norwegian registry. Diagnoses (absent/scanty, excessive, irregular/frequent menstruation, intermenstrual bleeding) general practitioner database. We examined new-onset Cox regression comparing vaccinated to unvaccinated women, where contributed follow-up time as until day vaccination. In addition, we conducted self-controlled case-series analysis, sensitivity analysis excluding all those who remained throughout pandemic, evaluate role unmeasured confounding. observed an increased risk several after against Covid-19, ranging adjusted HR (aHR) 1.18 (95% CI: 1.04, 1.33) for 1.29 1.23, 1.36) periods. However, estimates were fully attenuated when at end (aHRs 0.97 1.08). No differences identified according vaccine dose or type. Our case series confirmed no first vaccination, though there slightly 61 days with 2. conclusion, modestly appeared reflect confounding by never received vaccinations, associations did not remain compared before among ever women.

Язык: Английский

Процитировано

1

Monkeypox outbreak: after COVID-19, another challenge for the hemostatic system? DOI Open Access
Marco Marietta,

Valeria Coluccio,

Mario Luppi

и другие.

Internal and Emergency Medicine, Год журнала: 2022, Номер 17(8), С. 2179 - 2183

Опубликована: Окт. 4, 2022

Язык: Английский

Процитировано

6

COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance DOI Creative Commons

Nathalie Massy,

Marina Atzenhoffer,

Charlène Boulay

и другие.

Therapies, Год журнала: 2023, Номер 78(5), С. 489 - 498

Опубликована: Янв. 21, 2023

Язык: Английский

Процитировано

2

Hematological Questions in Personalized Management of COVID-19 Vaccination DOI Open Access
Tingting Wu, Junying Li, Yu Hu

и другие.

Journal of Personalized Medicine, Год журнала: 2023, Номер 13(2), С. 259 - 259

Опубликована: Янв. 30, 2023

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been causing a worldwide pandemic since 2019. Many vaccines have manufactured and shown promising results in reducing morbidity mortality. However, variety of vaccine-related adverse effects, including hematological events, reported, such as thromboembolic thrombocytopenia, bleeding. Moreover, new syndrome, vaccine-induced immune thrombotic following vaccination against COVID-19 recognized. These hematologic side effects also raised concerns about SARS-CoV-2 patients with preexisting conditions. Patients tumors are at higher risk infection, the efficacy safety this group remain uncertain attention. In review, we discuss events disorders.

Язык: Английский

Процитировано

2

Adenovirus Transcriptome in Human Cells Infected with ChAdOx1-Vectored Candidate HIV-1 Vaccine Is Dominated by High Levels of Correctly Spliced HIVconsv1&62 Transgene RNA DOI Creative Commons
David A. Matthews, Rachel Milligan,

Edmund G. Wee

и другие.

Vaccines, Год журнала: 2023, Номер 11(7), С. 1187 - 1187

Опубликована: Июль 1, 2023

We develop candidate HIV-1 vaccines, of which two components, ChAdOx1.tHIVconsv1 (C1) and ChAdOx1.HIVconsv62 (C62), are delivered by the simian adenovirus-derived vaccine vector ChAdOx1. Aberrant adenovirus RNA splicing involving transgene(s) coding for SARS-CoV-2 spike was suggested as an aetiology rare adverse events temporarily associated with initial deployment adenovirus-vectored vaccines during COVID-19 pandemic. Here, to eliminate this theoretically plausible phenomenon from list possible pathomechanisms our candidates, we directly sequenced mRNAs in C1- C62-infected nonpermissive MRC-5 A549 permissive HEK293 human cell lines. Our main observations cells, most similar those become infected after intramuscular administration into volunteers, were that (i) dominant vector-derived expected transcripts HIVconsvX immunogens (ii) atypical within synthetic open reading frame transgenes rare. conclude inadvertent is not a safety concern tested vaccines.

Язык: Английский

Процитировано

1

Paroxysmal Nocturnal Hemoglobinuria: A Case Report in a Pandemic Environment DOI Creative Commons
Vanda P. Peixoto,

Ana Carneiro,

Fernanda Trigo

и другие.

Reports — Medical Cases Images and Videos, Год журнала: 2023, Номер 6(3), С. 42 - 42

Опубликована: Сен. 8, 2023

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, rare, complement-mediated hemolytic anemia. PNH can be associated with marrow failure and thrombophilia. We present clinical report of splenic vein thrombosis in patient classic PNH. A 41-year-old male PNH, naïve to complement inhibitor therapy, developed as major adverse effect after vaccination protocol prevent meningococcal disease. also anticoagulant eculizumab treatment outcomes. In patients, should monitored outcome events, like vaccine-induced thrombosis. Eculizumab proves effective for treating intravascular hemolysis preventing more thrombotic events. The potential protective role on controlling activity consequent inflammation may help the not experience breakthrough when infected SARS-CoV-2. Extravascular remains present, but new molecules are being studied inhibit proximal there good health prospective patients.

Язык: Английский

Процитировано

1

A Randomized, Double Blind, Placebo-Controlled Study in Patients with Parkinson's Disease with an Alpha-Synuclein Vaccine UB-312 DOI
Pepijn Eijsvogel,

Hui‐Jing Yu,

Lauren Fedor

и другие.

Опубликована: Янв. 1, 2024

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

Язык: Английский

Процитировано

0

A Review of the Scientific Literature on Experimental Toxicity Studies of COVID-19 Vaccines, with Special Attention to Publications in Specific Toxicology Journals DOI Creative Commons
José L. Domingo

Опубликована: Июнь 25, 2024

Since the reports of first cases COVID-19, in less than 5 years a huge number documents regarding that disease and coronavirus (SARS-CoV-2), responsible for infection, have been published. The tremendous scientific covers many topics on different issues directly related to COVID-19/SARS-CoV-2. It includes studies about efficacy vaccines prevent disease. However, only comparatively low nonclinical -conducted experimental animals- focused potential adverse/toxic effects COVID-19 vaccines. present review was aimed at revising literature laboratory animals toxic/adverse In addition, investigations reported those specific toxicology journals with highest impact factors examined one by one. results indicate most nonclinical/experimental and/or candidates showed -in general terms- good safety profile. Only some animal were certain adverse found. rather surprising result has limited available (in databases PubMed Scopus) performed companies largest manufacturers mRNA world [https://www.google.com/search?sca_esv=ba085665fbb45bd4&sca_upv=1&q=Who+is+the+largest+manufacturer+of+vaccines+in+the+world%3F&sa=X&sqi=2&ved=2ahUKEwj6nMbAi-qGAxVLaqQEHTPwDcIQzmd6BAgZEAY]. Why these -assuming, course, they conducted- not published journals, allowing judgment international community, including toxicologists?

Язык: Английский

Процитировано

0

Global burden of vaccine-associated cutaneous immune-related adverse events, 1968–2024: An international pharmacovigilance study DOI
Jaehyeong Cho,

Hyesu Jo,

Damiano Pizzol

и другие.

Life Cycle, Год журнала: 2024, Номер 4

Опубликована: Ноя. 22, 2024

Язык: Английский

Процитировано

0

COVID vaccine-induced immune thrombotic thrombocytopenia: Rare but relevant DOI Open Access
Andreas Greinacher

European Journal of Internal Medicine, Год журнала: 2022, Номер 105, С. 20 - 22

Опубликована: Сен. 17, 2022

Язык: Английский

Процитировано

1